Efficacy and safety of PD-1 monoclonal antibody combined with interferon-alpha 1b and anlotinib hydrochloride as the second-line therapy in patients with unresectable advanced melanoma: A retrospective study.
Bolun ZhaoMengyu ZhangJingyi TangDaopei ZouFang LiuQiong ShiTianwen GaoChunying LiGuannan ZhuPublished in: Cancer medicine (2024)
PD-1 monoclonal antibody plus interferon-alpha 1b plus anlotinib showed acceptable tolerability and anticancer benefits in Chinese metastatic melanoma patients as a second-line therapy.
Keyphrases
- monoclonal antibody
- end stage renal disease
- dendritic cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- open label
- randomized controlled trial
- clinical trial
- squamous cell carcinoma
- peritoneal dialysis
- stem cells
- locally advanced
- immune response
- radiation therapy
- cell therapy
- mesenchymal stem cells
- patient reported